Access Pains After Approval In China? Consider The 'Three Ps'

Still a largely self-pay market, China is in the middle of a new drug approvals rush with 48 clearances in 2018 and more pending, forcing manufacturers to innovate their access models. Among several emerging strategies, a "Three P" combination of pricing, private insurance and patient assistance seems to be winning the day.

Bottles
'Three P' Strategy For High-Priced New Drugs In China • Source: Shutterstock

When a new drug gains approval in China, the road to the market is just beginning.

With the country poised to introduce many newly approved products including anticancers and anti-infectives to the market, making these accessible...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

China Unveils Multiple Policies To Support Innovative Drugs Throughout Life Cycle

 
• By 

China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.

To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says

 

FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.

China NMPA Lays Out Regulatory Priorities At DIA

 
• By 

At this year’s DIA China meeting, the national regulator updated its policy focus areas for this year, including clinical trial data protection and pilot projects to shorten IND approval times.

BIOSECURE Act Returning, Privacy, Gain-of-Function Bills Coming, Senate Sponsor Says

 

Legislation prohibiting work with certain Chinese biopharma firms will be reintroduced soon, Democratic Sen. Gary Peters said. And it will not be the only bill tied to international biotech competition and security concerns that will be considered.

More from Asia